{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:03:45Z","timestamp":1789625025761,"version":"build-2803163510"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) are a cornerstone of therapy for advanced non\u2013small cell lung cancer (NSCLC). Elderly patients remain underrepresented in clinical trials, and the prognostic significance of immune-related adverse events (irAEs)\u2014including their cumulative burden\u2014across age groups is not fully defined. This study evaluated age-related differences in clinical characteristics, treatment patterns, irAEs, and outcomes in patients with stage IV NSCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective multicenter study included 452 patients with metastatic NSCLC treated with ICIs, with or without chemotherapy. Patients were stratified by age (&amp;lt;75 vs. \u226575 years). irAEs were analyzed both by occurrence (yes vs. no) and by burden (\u22642 vs. &amp;gt;2 different irAE types). Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan\u2013Meier method and compared across age and irAE subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 452 patients, 344 (76.1%) were &amp;lt;75 years old and 108 (23.9%) were of ages \u226575 years. Baseline characteristics, including histology and PD-L1 expression, were comparable between age groups. Older patients were more frequently treated with immunotherapy alone or dual immunotherapy and less often received chemo-immunotherapy (p = 0.024). The distribution of irAEs differed significantly by age (p &amp;lt; 0.001), with patients \u226575 years of age experiencing a higher frequency of &amp;gt;2 irAE types. The median PFS and OS for the entire cohort were 12.0 and 15.0 months, respectively. While PFS was similar between age groups, OS was significantly shorter in patients of age \u226575 years (p = 0.008). Across both age groups, the occurrence of irAEs was associated with significantly improved PFS and OS. A higher irAE burden (&amp;gt;2 different types) was associated with numerically longer survival in both younger and older patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ICIs are effective in elderly patients with advanced NSCLC. The presence of irAEs\u2014and potentially a higher irAE burden\u2014is associated with improved survival outcomes regardless of age, supporting irAEs as a clinically meaningful biomarker of immunotherapy benefit, including in patients \u226575 years of age.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1947761","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:32:19Z","timestamp":1789623139000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune-related adverse events and clinical outcomes in advanced non-small cell lung cancer: does more toxicity predict better outcomes?"],"prefix":"10.3389","volume":"17","author":[{"given":"Abed","family":"Agbarya","sequence":"first","affiliation":[{"name":"Department of Oncology, Bnai Zion Medical Center","place":["Haifa, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa Shani","family":"Shrem","sequence":"additional","affiliation":[{"name":"The Legacy Heritage Cancer Center, Larry Norton Institute, Soroka Medical Center","place":["Beer Sheva, Israel"]},{"name":"Faculty of Health Sciences, Ben Gurion University of the Negev","place":["Beer Sheva, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmah","family":"Miari","sequence":"additional","affiliation":[{"name":"Department of Oncology, Meir Medical Center","place":["Kfar Saba, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronen","family":"Brenner","sequence":"additional","affiliation":[{"name":"Edith Wolfson Medical Center, Oncology Institute","place":["Holon, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia","family":"Dudnik","sequence":"additional","affiliation":[{"name":"The Legacy Heritage Cancer Center, Larry Norton Institute, Soroka Medical Center","place":["Beer Sheva, Israel"]},{"name":"Faculty of Health Sciences, Ben Gurion University of the Negev","place":["Beer Sheva, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Maimon Rabinovich","sequence":"additional","affiliation":[{"name":"Department of Oncology, Meir Medical Center","place":["Kfar Saba, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amichay","family":"Meirovitz","sequence":"additional","affiliation":[{"name":"The Legacy Heritage Cancer Center, Larry Norton Institute, Soroka Medical Center","place":["Beer Sheva, Israel"]},{"name":"Faculty of Health Sciences, Ben Gurion University of the Negev","place":["Beer Sheva, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Yakobson","sequence":"additional","affiliation":[{"name":"The Legacy Heritage Cancer Center, Larry Norton Institute, Soroka Medical Center","place":["Beer Sheva, Israel"]},{"name":"Faculty of Health Sciences, Ben Gurion University of the Negev","place":["Beer Sheva, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahron Yehonatan","family":"Cohen","sequence":"additional","affiliation":[{"name":"The Legacy Heritage Cancer Center, Larry Norton Institute, Soroka Medical Center","place":["Beer Sheva, Israel"]},{"name":"Faculty of Health Sciences, Ben Gurion University of the Negev","place":["Beer Sheva, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nashat","family":"Abu Yasin","sequence":"additional","affiliation":[{"name":"The Legacy Heritage Cancer Center, Larry Norton Institute, Soroka Medical Center","place":["Beer Sheva, Israel"]},{"name":"Faculty of Health Sciences, Ben Gurion University of the Negev","place":["Beer Sheva, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adan","family":"Khalaily","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Ben Gurion University of the Negev","place":["Beer Sheva, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raya","family":"Bdair","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Ben Gurion University of the Negev","place":["Beer Sheva, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Abu Amna","sequence":"additional","affiliation":[{"name":"Department of Oncology, Emek Medical Centre","place":["Afula, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Shalata","sequence":"additional","affiliation":[{"name":"The Legacy Heritage Cancer Center, Larry Norton Institute, Soroka Medical Center","place":["Beer Sheva, Israel"]},{"name":"Faculty of Health Sciences, Ben Gurion University of the Negev","place":["Beer Sheva, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/medsci13030142","article-title":"Current and emerging therapeutic strategies for limited- and extensive-stage small-cell lung cancer","volume":"13","author":"Shalata","year":"2025","journal-title":"Med Sci (Basel)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3775","article-title":"Non-small-cell lung cancers: a heterogeneous set of diseases","volume":"14","author":"Chen","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k793","article-title":"Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis","volume":"360","author":"Baxi","year":"2018","journal-title":"BMJ"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1197364","article-title":"Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases","volume":"14","author":"Ibis","year":"2023","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1172\/JCI170503","article-title":"Pulmonary toxicity of immune checkpoint immunotherapy","volume":"134","author":"Ghanbar","year":"2024","journal-title":"J Clin Invest"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16112159","article-title":"Real-world prevalence and tolerability of immune-related adverse events in older adults with non-small cell lung cancer: a multi-institutional retrospective study","volume":"16","author":"Matsukane","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s12885-023-10701-z","article-title":"A text-mining approach to study the real-world effectiveness and potentially fatal immune-related adverse events of PD-1 and PD-L1 inhibitors in older patients with stage III\/IV non-small cell lung cancer","volume":"23","author":"Abedian Kalkhoran","year":"2023","journal-title":"BMC Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.708195","article-title":"Immune-related adverse events associated with outcomes in patients with NSCLC treated with anti-PD-1 inhibitors: a systematic review and meta-analysis","volume":"11","author":"Zhao","year":"2021","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1190001","article-title":"Association between immune-related adverse events and immunotherapy efficacy in non-small-cell lung cancer: a meta-analysis","volume":"14","author":"Lin","year":"2023","journal-title":"Front Pharmacol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1177\/10781552241243042","article-title":"The relationship between immune-related adverse events during ipilimumab monotherapy and survival outcomes among melanoma patients: a systematic review","volume":"31","author":"Sheng","year":"2025","journal-title":"J Oncol Pharm Pract"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.3085","article-title":"Lung cancer in the elderly","volume":"25","author":"Gridelli","year":"2007","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.08.003","article-title":"Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter","volume":"60","author":"Ferrara","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"B19","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1093\/annonc\/mdp360","article-title":"Experts' opinion for the treatment of non-small-cell lung cancer in an elderly population","volume":"21","author":"Pallis","year":"2010","journal-title":"Ann Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2005.06.003","article-title":"Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG)","volume":"55","author":"Extermann","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.05.015","article-title":"Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme","volume":"100","author":"Grossi","year":"2018","journal-title":"Eur J Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2021.04.007","article-title":"Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer","volume":"156","author":"Waterhouse","year":"2021","journal-title":"Lung Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2017.02.001","article-title":"Immunotherapy comes of age: Immune aging & checkpoint inhibitors","volume":"8","author":"Elias","year":"2017","journal-title":"J Geriatr Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s40425-019-0645-6","article-title":"Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance","volume":"7","author":"Couey","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.07.004","article-title":"Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies","volume":"135","author":"Nosaki","year":"2019","journal-title":"Lung Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.lungcan.2019.08.030","article-title":"Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer","volume":"137","author":"Galli","year":"2019","journal-title":"Lung Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1415470","article-title":"Immune-related adverse events in patients treated with immunotherapy for locally advanced or metastatic NSCLC in real-world settings: a systematic review and meta-analysis","volume":"14","author":"Pasello","year":"2024","journal-title":"Front Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.05.010","article-title":"Safety, efficacy, and patient-reported health-related quality of life and symptom burden with nivolumab in patients with advanced non-small cell lung cancer, including patients aged 70 years or older or with poor performance status (CheckMate 153)","volume":"14","author":"Spigel","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.11.011","article-title":"Impact of age on outcomes with immunotherapy in patients with non-small cell lung cancer","volume":"14","author":"Lichtenstein","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0384","article-title":"Association of immune-related adverse events with clinical benefit in patients with advanced non-small-cell lung cancer treated with nivolumab","volume":"23","author":"Toi","year":"2018","journal-title":"Oncologist"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2018.10.002","article-title":"Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer","volume":"20","author":"Grangeon","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"B36","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.52302","article-title":"Immune-related adverse events and survival among patients with metastatic NSCLC treated with immune checkpoint inhibitors","volume":"7","author":"Cook","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.5012","article-title":"Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer","volume":"6","author":"Shankar","year":"2020","journal-title":"JAMA Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1947761\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:32:20Z","timestamp":1789623140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1947761\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2026.1947761"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1947761","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"article-number":"1947761"}}